Story perspectives

Dr Reddy’s, Takeda sign Qdenga private-market distribution deal

By Drooid · Sep 19, 2026, 4:11 AM UTC · How we work

Summary

Story summary

Dr Reddy’s Laboratories signed an agreement with Takeda Pharmaceutical to distribute Qdenga dengue vaccine in India’s private market.
The Central Drugs Standard Control Organisation approved Qdenga for ages 4-60 in July 2026, making it India’s first dengue vaccine.
Takeda will retain promotion and distribution rights for Qdenga in India’s public market and oversee medical matters.
Dr Reddy’s will handle promotion, distribution, healthcare-professional engagement and disease-awareness for Qdenga’s private-market launch.

History

Historical Context

In 2016, Sanofi’s Dengvaxia became the world’s first licensed dengue vaccine, receiving approval from the Philippines Department of Health. The rollout distributed 2.5 million doses, yet a 2017 WHO safety review linked the vaccine to increased severe disease in seronegative children, prompting a 30% drop in public confidence. Today, Dr Reddy’s Laboratories and Takeda’s private-market partnership for Qdenga mirrors Sanofi’s earlier public-sector launch, aiming to avoid past pitfalls by separating promotion and medical oversight. The experience underscores that robust regulatory scrutiny and transparent communication are essential to sustain vaccine uptake and protect India’s 30 million dengue-prone population.

1 of 2

Story summary

Dr Reddy’s Laboratories signed an agreement with Takeda Pharmaceutical to distribute Qdenga dengue vaccine in India’s private market.
The Central Drugs Standard Control Organisation approved Qdenga for ages 4-60 in July 2026, making it India’s first dengue vaccine.
Takeda will retain promotion and distribution rights for Qdenga in India’s public market and oversee medical matters.
Dr Reddy’s will handle promotion, distribution, healthcare-professional engagement and disease-awareness for Qdenga’s private-market launch.

1 / 2